Glauben als Grundlage - Die Rezeption Michael Polanyis im Gespräch von Theologie und Naturwissenschaften

Das Konzept des „Glaubens“ ist eine zentrale Grundlage von Polanyis Wissenschaftstheorie, und schon früh hat er sich explizit mit dem Verhältnis von Religion und Wissenschaft beschäftigt. Entsprechend wohlwollend ist seine Philosophie im Gespräch von Theologie und Naturwissenschaften aufgenommen worden. Seine deutschsprachige Rezeption blieb dabei bislang recht spärlich, während er in dem angelsächsischen Gespräch der Wissenschaften früh reiche Wirkung entfaltet und nahezu paradigmatische Bedeutung gewonnen hat. Die 2005 erschienene umfangreiche Polanyibiographie von William T. Scott und Martin X. Moleski, S.J. informiert auch über die Facetten von Polanyis eigenen Glauben. Sie stellt damit eine wesentliche Interpretationshilfe da, wie man eine Streitfrage der angelsächsischen Polanyi-Rezeption betreffs der Realität des Gegenstandes der Religion in seiner Philosophie beurteilen kann. Es ist davon auszugehen, dass er mit Tillich den Existenzbegriff in seiner Anwendung auf Gott abgelehnt hat und die Gelwick/Torrance-Prosch-Debatte, die um die Frage der unabhängigen Existenz Gottes in Polanyis Denken kreist, deswegen mehr oder weniger sinnlos ist.

Elevated AST-to-platelet ratio index is associated with increased all-cause mortality among HIV-infected adults in Zambia.

BACKGROUND AND AIMS We investigated the association between significant liver fibrosis, determined by AST-to-platelet ratio index (APRI), and all-cause mortality among HIV-infected patients prescribed antiretroviral therapy (ART) in Zambia METHODS: Among HIV-infected adults who initiated ART, we categorized baseline APRI scores according to established thresholds for significant hepatic fibrosis (APRI ≥1.5) and cirrhosis (APRI ≥2.0). Using multivariable logistic regression we identified risk factors for elevated APRI including demographic characteristics, body mass index (BMI), HIV clinical and immunologic status, and tuberculosis. In the subset tested for hepatitis B surface antigen (HBsAg), we investigated the association of hepatitis B virus co-infection with APRI score. Using Kaplan-Meier analysis and Cox proportional hazards regression we determined the association of elevated APRI with death during ART. RESULTS Among 20,308 adults in the analysis cohort, 1,027 (5.1%) had significant liver fibrosis at ART initiation including 616 (3.0%) with cirrhosis. Risk factors for significant fibrosis or cirrhosis included male sex, BMI <18, WHO clinical stage 3 or 4, CD4+ count <200 cells/mm(3) , and tuberculosis. Among the 237 (1.2%) who were tested, HBsAg-positive patients had four times the odds (adjusted odds ratio, 4.15; 95% CI, 1.71-10.04) of significant fibrosis compared HBsAg-negatives. Both significant fibrosis (adjusted hazard ratio 1.41, 95% CI, 1.21-1.64) and cirrhosis (adjusted hazard ratio 1.57, 95% CI, 1.31-1.89) were associated with increased all-cause mortality. CONCLUSION Liver fibrosis may be a risk factor for mortality during ART among HIV-infected individuals in Africa. APRI is an inexpensive and potentially useful test for liver fibrosis in resource-constrained settings. This article is protected by copyright. All rights reserved.

16p11.2 600 kb Duplications confer risk for typical and atypical Rolandic epilepsy

Rolandic epilepsy (RE) is the most common idiopathic focal childhood epilepsy. Its molecular basis is largely unknown and a complex genetic etiology is assumed in the majority of affected individuals. The present study tested whether six large recurrent copy number variants at 1q21, 15q11.2, 15q13.3, 16p11.2, 16p13.11 and 22q11.2 previously associated with neurodevelopmental disorders also increase risk of RE. Our association analyses revealed a significant excess of the 600 kb genomic duplication at the 16p11.2 locus (chr16: 29.5-30.1 Mb) in 393 unrelated patients with typical (n = 339) and atypical (ARE; n = 54) RE compared with the prevalence in 65,046 European population controls (5/393 cases versus 32/65,046 controls; Fisher's exact test P = 2.83 × 10(-6), odds ratio = 26.2, 95% confidence interval: 7.9-68.2). In contrast, the 16p11.2 duplication was not detected in 1738 European epilepsy patients with either temporal lobe epilepsy (n = 330) and genetic generalized epilepsies (n = 1408), suggesting a selective enrichment of the 16p11.2 duplication in idiopathic focal childhood epilepsies (Fisher's exact test P = 2.1 × 10(-4)). In a subsequent screen among children carrying the 16p11.2 600 kb rearrangement we identified three patients with RE-spectrum epilepsies in 117 duplication carriers (2.6%) but none in 202 carriers of the reciprocal deletion. Our results suggest that the 16p11.2 duplication represents a significant genetic risk factor for typical and atypical RE.

Der rettende Begleiter. Der Erzengel Michael ist mehr als nur der Engel, der mit dem Teufel kämpft

Ein Artikel über die Figur des Erzengels Michael und das theologische Engelsverständnis in einer kirchlichen Zeitschrift für ein allgemeines Publikum.

Wissenschaft und Glauben bei Michael Polanyi

For Michael Polanyi, religion and science fight abreast to protect the occidental culture from totalitarian threat. Both are belief-based endeavors, Polanyi is convinced. While this is not surprising at all regarding religion, it is surely a provocation regarding science. The article tries to explore this original thought of Polanyi and to examine how it is rooted in his personal convictions and beliefs. Special emphasis is given to Polanyi’s critique of contemporary biology, as expressed in his article on “Science and Religion”, in some ways a response to Paul Tillich’s theology. Contemporary biology’s findings undermine exactly what Polanyi is fighting for, hence he is convinced that its findings are somewhat flawed. This should however not lead to the false conclusion that Polanyi had anything to do with creationism or would have favored Intelligent Design in our days.

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

We studied the influence of comorbidities on remission rate and overall survival (OS) in patients with chronic myeloid leukemia (CML). Participants of the CML Study IV, a randomized 5-arm trial designed to optimize imatinib therapy, were analyzed for comorbidities at diagnosis using the Charlson Comorbidity Index (CCI); 511 indexed comorbidities were reported in 1519 CML patients. Age was an additional risk factor in 863 patients. Resulting CCI scores were as follows: CCI 2, n = 589; CCI 3 or 4, n = 599; CCI 5 or 6, n = 229; and CCI ≥ 7, n = 102. No differences in cumulative incidences of accelerated phase, blast crisis, or remission rates were observed between patients in the different CCI groups. Higher CCI was significantly associated with lower OS probabilities. The 8-year OS probabilities were 93.6%, 89.4%, 77.6%, and 46.4% for patients with CCI 2, 3 to 4, 5 to 6, and ≥7, respectively. In multivariate analysis, CCI was the most powerful predictor of OS, which was still valid after removal of its age-related components. Comorbidities have no impact on treatment success but do have a negative effect on OS, indicating that survival of patients with CML is determined more by comorbidities than by CML itself. OS may therefore be inappropriate as an outcome measure for specific CML treatments. The trial was registered at www.clinicaltrials.gov as #NCT00055874.